MA59968B1 - Composés de cyclobutyle dihydroquinoléine sulfonamide - Google Patents
Composés de cyclobutyle dihydroquinoléine sulfonamideInfo
- Publication number
- MA59968B1 MA59968B1 MA59968A MA59968A MA59968B1 MA 59968 B1 MA59968 B1 MA 59968B1 MA 59968 A MA59968 A MA 59968A MA 59968 A MA59968 A MA 59968A MA 59968 B1 MA59968 B1 MA 59968B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- dihydroquinoline
- cyclobutyl
- relates
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un composé de cyclobutyl dihydroquinoléine sulfonamide de formule (I), un énantiomère, un diastéréoisomère, un atropisomère de celui-ci, un mélange de ceux-ci, ou un sel pharmaceutiquement acceptable de celui-ci, qui inhibe des canaux sodiques voltage-dépendants, en particulier Nav1.7. Les composés sont utiles pour le traitement de maladies associées à l'activité de canaux sodiques tels que les troubles de la douleur, la toux et la démangeaison. L'invention concerne également des compositions pharmaceutiques contenant les composés de la présente invention. L'invention concerne en outre une préparation atropi-sélective desdits composés de Formule (I), et un intermédiaire de ceux-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037001P | 2020-06-10 | 2020-06-10 | |
| PCT/US2021/036896 WO2021252820A1 (fr) | 2020-06-10 | 2021-06-10 | Composés de cyclobutyle dihydroquinoléine sulfonamide |
| EP21737878.5A EP4165024B1 (fr) | 2020-06-10 | 2021-06-10 | Composés de cyclobutyle dihydroquinoléine sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59968B1 true MA59968B1 (fr) | 2025-10-31 |
Family
ID=76797115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59968A MA59968B1 (fr) | 2020-06-10 | 2021-06-10 | Composés de cyclobutyle dihydroquinoléine sulfonamide |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US12240839B2 (fr) |
| EP (2) | EP4653050A3 (fr) |
| JP (2) | JP7739051B2 (fr) |
| KR (1) | KR20230022996A (fr) |
| CN (2) | CN115697971B (fr) |
| AR (1) | AR122592A1 (fr) |
| AU (1) | AU2021288696B2 (fr) |
| BR (1) | BR112022025201A2 (fr) |
| CA (1) | CA3183889A1 (fr) |
| CL (1) | CL2022003499A1 (fr) |
| CO (1) | CO2022017903A2 (fr) |
| CR (1) | CR20220631A (fr) |
| DK (1) | DK4165024T3 (fr) |
| ES (1) | ES3037072T3 (fr) |
| FI (1) | FI4165024T3 (fr) |
| HR (1) | HRP20251229T1 (fr) |
| HU (1) | HUE072945T2 (fr) |
| IL (2) | IL326793A (fr) |
| JO (1) | JOP20220334A1 (fr) |
| LT (1) | LT4165024T (fr) |
| MA (1) | MA59968B1 (fr) |
| MX (2) | MX2022015856A (fr) |
| PE (1) | PE20230860A1 (fr) |
| PL (1) | PL4165024T3 (fr) |
| PT (1) | PT4165024T (fr) |
| RS (1) | RS67268B1 (fr) |
| SI (1) | SI4165024T1 (fr) |
| SM (1) | SMT202500328T1 (fr) |
| TW (1) | TWI899251B (fr) |
| UY (1) | UY39263A (fr) |
| WO (1) | WO2021252820A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7880201B2 (ja) * | 2020-06-10 | 2026-06-25 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| SMT202600064T1 (it) | 2021-06-04 | 2026-03-09 | Vertex Pharma | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide |
| WO2022256842A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CA3221939A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques |
| EP4385978A4 (fr) * | 2021-08-12 | 2025-08-13 | Tyk Medicines Inc | Composé polycyclique et son utilisation |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (fr) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4412994A (en) | 1980-04-24 | 1983-11-01 | Interx Research Corporation | Mannich-base hydroxamic acid prodrugs, compositions and use |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US5707985A (en) | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
| PA8444901A1 (es) | 1997-01-28 | 2000-05-24 | Hoffmann La Roche | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios |
| US6858621B2 (en) | 2002-04-26 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| CA2511089A1 (fr) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | Antagonistes du recepteur des androgenes |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| WO2006117762A2 (fr) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Agents antimicrobiens |
| CN101218235A (zh) | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| EP1888558B1 (fr) | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Derives bicycliques en tant que modulateurs de canaux ioniques |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| WO2010045197A1 (fr) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Composés spiro-oxindole et leur utilisation comme agents thérapeutiques |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102471235A (zh) | 2009-07-11 | 2012-05-23 | 拜耳医药股份有限公司 | 利用环烷基的放射性标记方法 |
| CN102030780B (zh) * | 2010-10-26 | 2014-01-29 | 浙江大学 | 一种手性螺环磷酸和制备方法及其应用 |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| WO2013086229A1 (fr) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
| WO2013122897A1 (fr) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| CN107406380B (zh) * | 2015-02-04 | 2020-04-28 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| AU2016226340B2 (en) | 2015-03-02 | 2019-11-07 | Amgen Inc. | Bicyclic ketone sulfonamide compounds |
| MY197595A (en) | 2015-12-18 | 2023-06-27 | Amgen Inc | Alkyl dihydroquinoline sulfonamide compounds |
| WO2017106872A1 (fr) | 2015-12-18 | 2017-06-22 | Amgen Inc | Composés sulfonamides de dihydroquinoline d'alcynyle |
| JP2019512519A (ja) | 2016-03-21 | 2019-05-16 | ザ スクリプス リサーチ インスティテュート | Ｐｄ（ＩＩ）触媒エナンチオ選択的β−メチレンＣ（ｓｐ３）−Ｈ結合活性化 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP7880201B2 (ja) * | 2020-06-10 | 2026-06-25 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| EP4385978A4 (fr) | 2021-08-12 | 2025-08-13 | Tyk Medicines Inc | Composé polycyclique et son utilisation |
| JP2024529736A (ja) | 2021-08-19 | 2024-08-08 | アムジエン・インコーポレーテツド | トランスハロシクロブタンの立体選択的調製 |
-
2021
- 2021-05-31 JP JP2021090960A patent/JP7739051B2/ja active Active
- 2021-06-10 DK DK21737878.5T patent/DK4165024T3/da active
- 2021-06-10 CN CN202180040963.2A patent/CN115697971B/zh active Active
- 2021-06-10 ES ES21737878T patent/ES3037072T3/es active Active
- 2021-06-10 EP EP25188659.4A patent/EP4653050A3/fr active Pending
- 2021-06-10 TW TW110121155A patent/TWI899251B/zh active
- 2021-06-10 MX MX2022015856A patent/MX2022015856A/es unknown
- 2021-06-10 JO JOP/2022/0334A patent/JOP20220334A1/ar unknown
- 2021-06-10 HR HRP20251229TT patent/HRP20251229T1/hr unknown
- 2021-06-10 IL IL326793A patent/IL326793A/en unknown
- 2021-06-10 WO PCT/US2021/036896 patent/WO2021252820A1/fr not_active Ceased
- 2021-06-10 MA MA59968A patent/MA59968B1/fr unknown
- 2021-06-10 SI SI202130354T patent/SI4165024T1/sl unknown
- 2021-06-10 SM SM20250328T patent/SMT202500328T1/it unknown
- 2021-06-10 RS RS20250992A patent/RS67268B1/sr unknown
- 2021-06-10 US US17/633,151 patent/US12240839B2/en active Active
- 2021-06-10 PE PE2022002892A patent/PE20230860A1/es unknown
- 2021-06-10 BR BR112022025201A patent/BR112022025201A2/pt unknown
- 2021-06-10 FI FIEP21737878.5T patent/FI4165024T3/fi active
- 2021-06-10 KR KR1020237000972A patent/KR20230022996A/ko active Pending
- 2021-06-10 UY UY0001039263A patent/UY39263A/es unknown
- 2021-06-10 CR CR20220631A patent/CR20220631A/es unknown
- 2021-06-10 CN CN202510007130.6A patent/CN119735588A/zh active Pending
- 2021-06-10 PT PT217378785T patent/PT4165024T/pt unknown
- 2021-06-10 AU AU2021288696A patent/AU2021288696B2/en active Active
- 2021-06-10 LT LTEPPCT/US2021/036896T patent/LT4165024T/lt unknown
- 2021-06-10 CA CA3183889A patent/CA3183889A1/fr active Pending
- 2021-06-10 AR ARP210101586A patent/AR122592A1/es unknown
- 2021-06-10 PL PL21737878.5T patent/PL4165024T3/pl unknown
- 2021-06-10 HU HUE21737878A patent/HUE072945T2/hu unknown
- 2021-06-10 EP EP21737878.5A patent/EP4165024B1/fr active Active
- 2021-06-11 US US17/344,947 patent/US20210387978A1/en not_active Abandoned
-
2022
- 2022-11-17 IL IL298325A patent/IL298325B2/en unknown
- 2022-12-09 MX MX2025010506A patent/MX2025010506A/es unknown
- 2022-12-09 CL CL2022003499A patent/CL2022003499A1/es unknown
- 2022-12-09 CO CONC2022/0017903A patent/CO2022017903A2/es unknown
-
2025
- 2025-01-28 US US19/039,379 patent/US20250171425A1/en active Pending
- 2025-09-02 JP JP2025145171A patent/JP2025179137A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025010506A (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| MX2022015622A (es) | Compuestos de dihidroquinolin sulfonamida de ciclopropilo. | |
| MA58181B1 (fr) | Composés tricycliques substitués | |
| MA27937A1 (fr) | Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire | |
| MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| MA28746B1 (fr) | Dérivés de quinazoline-4-yl-pipéridine et cinnoline-4-yl-pipéridine servant d'inhibiteurs de PDE10 pour le traitement de troubles du SNC | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA27665A1 (fr) | Triazoles substitues diaryle comme bloqueurs des canaux sodiques | |
| MX2024015961A (es) | Compuesto de 3,4-dihidroquinolin-2 (1h)-ona | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques | |
| MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| MA68743B1 (fr) | Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa | |
| MA52375A1 (fr) | Inhibiteurs de cdk8/19 |